One point of interest from the recent announcement on Board Renewal is the highlighting of Dr Robert Hayes experience in forming partnerships between biotech companies and university partners. It perhaps is just another pointer that Phylogica has moved towards the multidisciplinary model of drug discovery and development advocated by the Grand Challenge advisory panel.
The calibre of the appointment of Dr Rick Kendall is highlighted by the international prestige enjoyed by Kite Pharma. Kite recently won the Clinical Trial Result of the Year for its CAR-T trial of Axicabtagene. Kendall, VP Research at Kite with responsibility for developing CAR-T technology would appear to be highly qualified to advise Phylogica in its drug development program.
PYC Price at posting:
3.7¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)